<DOC>
	<DOCNO>NCT00968617</DOCNO>
	<brief_summary>This study define effective start dose subcutaneous administration MK2578 correct anemia erythropoiesis-stimulating agent ( ESA ) -naive patient chronic kidney disease ( CKD ) dialysis evaluate safety .</brief_summary>
	<brief_title>A Study MK2578 Patients With Chronic Kidney Disease Who Are Not Dialysis ( 2578-002 )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Patient male female either child agree use appropriate contraceptive measure Patient chronic kidney disease Patient morbidly obese Patient use another erythropoiesis ( red blood cell formation ) stimulating agent within 12 week screen Patient require dialysis study plan kidney transplant within next 6 month Patient blood transfusion within 12 week screen Patient major surgery within past 12 week plan surgery Patient Human Immunodeficiency Virus ( HIV ) Patient history disease CKD know cause anemia Patient severe congestive heart failure Patient history malignant cancer , except certain skin cervical cancer Patient history grand mal seizure within last 6 month Patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Anemia</keyword>
</DOC>